Redeye briefly comments on Guard Therapeutics announcing additional encouraging data from its completed phase IIa study AKITA, which investigated RMC-035 as a renal protective agent during open-heart surgery. Furthermore, the company announced that topline results from the phase IIb study POINTER are anticipated in early November.
LÄS MER